MederiAI targets the gut to save lives
Endoscopies are vital procedures in detecting life threatening conditions, but they can often be slow, invasive and subject to human error – MederiAI aims to change that.
MederiAI is developing an AI-powered software solution that assists gastroenterologists in analysing capsule endoscopy videos faster, more accurately, and at a significantly lower cost. Capsule endoscopy is a non-invasive procedure in which a patient swallows a small capsule equipped with a camera that records hours of footage of the gastrointestinal tract. However, currently reviewing this footage typically takes around two hours per case, is prone to human error, and leads to critical conditions being missed in up to 25% of cases. MederiAI’s solution helps doctors detect life-threatening conditions in under 10 minutes, dramatically reducing diagnostic time and increasing accuracy — ultimately saving lives and improving patient care.
Doctors upload capsule endoscopy videos directly to MederiAI’s platform, where their AI automatically analyses the footage and delivers accurate results. If a life-threatening condition is detected, the doctor is notified immediately. Otherwise, they can review the video at their own convenience by simply accepting or rejecting the AI’s predictions—confident in the knowledge that no urgent conditions have been missed.
But training the AI has certainly not been an easy quest for the team behind MederiAI. One of their biggest hurdles have been accessing high-quality, annotated medical data — especially in a field like gastroenterology where labeling is complex and requires deep clinical expertise. Equally, building partnerships with hospitals and especially navigating regulatory landscapes are tough (and expensive) challenges for a young startup. But they didn’t give up, and have started collaborating with regulatory and compliance consultants to ensure they meet the necessary standards and develop the required technical documentation as part of the CE certification process. Additionally, they partnered with medical advisors who are instrumental in advancing their clinical trials, helping them navigate both the scientific and regulatory aspects of validating the solutions.
Alongside Accelerace the Italian accelerator VITA and US-based Plug And Play have invested in MederiAI.
“Getting the backing of Accelerace and joining the Allstar programme has been an incredible opportunity for us. Their network, experience, and hands-on support have helped us navigate the early hurdles of being a deep-tech medical startup. We’re thrilled to be part of such a forward-thinking ecosystem.”
— Adrian, CEO & Co-founder, MederiAI
The team behind MederiAI will use the investment to run their clinical study in Spain with Sanitas, Hospital de Bellvitge and Hospital Clínico San Carlos, develop their proprietary annotation platform and main platform, as well as train the first version of the spatiotemporal AI on clinical data. They aim to validate their AI in 2025, perform clinical trials in 2026 and obtain certification and launch commercially in Europe in 2027.